Skip to Content

Insulin Glargine

In the US, Insulin Glargine (insulin glargine systemic) is a member of the drug class insulin and is used to treat Diabetes - Type 1 and Diabetes - Type 2.

US matches:



ATC (Anatomical Therapeutic Chemical Classification)


CAS registry number (Chemical Abstracts Service)


Chemical Formula


Molecular Weight


Therapeutic Categories

Antidiabetic agent

Insulin analogue, recombinant human

Chemical Name

21A-Glycine-30Ba-L-arginine-30Bb-L-arginineinsulin (human) (WHO)

Foreign Names

  • Insulinum glarginum (Latin)
  • Insulin glargin (German)
  • Insuline glargine (French)
  • Insulina glargina (Spanish)

Generic Names

Brand Names

    Eli Lilly and Company, United Kingdom; Lilly, France
  • Abasaglar
    Eli Lilly, Switzerland; Eli Lilly, Poland; Lilly, Slovakia; Lilly France, Macedonia
  • Abasria
    Eli Lilly, Croatia (Hrvatska)
  • Apidra
    Sanofi Aventis, China
  • Basaglar
    Eli Lilly and Company, United States
  • Basalin
    Gan & Lee, Thailand; LG Life Sciences, Thailand
  • Basalog
    Biocon, India
  • Chang Xiu Lin
    Beijing Ganli Pharmaceutical Group, China
  • Glarine
    ACI, Bangladesh
  • Lantaus
    Sanofi-Aventis, Bangladesh
  • Lantus
    Aventis, Brazil; Aventis Pharma, Greece; Sanofi, Dominican Republic; Sanofi, United Kingdom; Sanofi, Guatemala; Sanofi, Ireland; Sanofi, Japan; Sanofi, Panama; Sanofi, Sweden; Sanofi Aventis, Chile; Sanofi Aventis, China; Sanofi Aventis, Spain; Sanofi Aventis, India; Sanofi Oy, Finland; Sanofi-Aventis, Argentina; Sanofi-Aventis, Austria; Sanofi-Aventis, Australia; Sanofi-Aventis, Bosnia & Herzegowina; Sanofi-Aventis, Bangladesh; Sanofi-Aventis, Belgium; Sanofi-Aventis, Switzerland; Sanofi-Aventis, Colombia; Sanofi-Aventis, Germany; Sanofi-Aventis, Denmark; Sanofi-Aventis, Ecuador; Sanofi-Aventis, Egypt; Sanofi-Aventis, France; Sanofi-Aventis, Georgia; Sanofi-Aventis, Hong Kong; Sanofi-Aventis, Honduras; Sanofi-Aventis, Hungary; Sanofi-Aventis, Indonesia; Sanofi-Aventis, Iceland; Sanofi-Aventis, Italy; Sanofi-Aventis, South Korea; Sanofi-Aventis, Lithuania; Sanofi-Aventis, Latvia; Sanofi-Aventis, Mexico; Sanofi-Aventis, Malaysia; Sanofi-Aventis, Nicaragua; Sanofi-Aventis, Netherlands; Sanofi-Aventis, Norway; Sanofi-Aventis, New Zealand; Sanofi-Aventis, Oman; Sanofi-Aventis, Peru; Sanofi-Aventis, Philippines; Sanofi-Aventis, Poland; Sanofi-Aventis, Portugal; Sanofi-Aventis, Romania; Sanofi-Aventis, Serbia; Sanofi-Aventis, Singapore; Sanofi-Aventis, Slovakia; Sanofi-Aventis, El Salvador; Sanofi-Aventis, Thailand; Sanofi-Aventis, Tunisia; Sanofi-Aventis, Turkey; Sanofi-Aventis, Taiwan; Sanofi-Aventis, Vietnam; Sanofi-Aventis, South Africa; Sanofi-Aventis Group, Russian Federation; Yousuf Mahmood Husain, Bahrain
  • Optisulin
    Sanofi-Aventis, Lithuania; Sanofi-Aventis, Netherlands; Sanofi-Aventis, Poland
  • Toujeo
    Sanofi, United Kingdom; Sanofi-Aventis, Switzerland; Sanofi-Aventis, Germany
  • Vibrenta
    Incepta, Bangladesh


BANBritish Approved Name
ISInofficial Synonym
JANJapanese Accepted Name
OSOfficial Synonym
PHPharmacopoeia Name
Rec.INNRecommended International Nonproprietary Name (World Health Organization)
USANUnited States Adopted Name
WHOWorld Health Organization

Further information on drug naming conventions: International Nonproprietary Names.

Important Notice: The international database is in BETA release. This means it is still under development and may contain inaccuracies. It is not intended as a substitute for the expertise and judgement of your physician, pharmacist or other healthcare professional. It should not be construed to indicate that the use of any medication in any country is safe, appropriate or effective for you. Consult with your healthcare professional before taking any medication.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.